Cooperative Agreement U01HL081649

Federal Cooperative Agreement Award Summary Award Overview Artery Therapeutics, Inc. received a $2.64 million Cooperative Agreement from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), awarded February 15, 2026, with an ultimate completion date of March 15, 2028. The awardee will conduct clinical research and development services for CS6253, an ABCA1 (ATP-binding-cassette-transporter A1) agonist therapeutic candidate targeting hereditary APOE4...

Federal Project Grant Award Summary Artery Therapeutics, Inc. received a $2.45 million Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866) awarded September 10, 2025, with completion targeted for August 31, 2026. The primary deliverable is the manufacturing of approximately 2.3 kilograms of Good Manufacturing Practice (GMP)-compliant CS6253, an ATP-binding cassette transporter A1 (ABCA1) agonist small molecule peptide, to support chronic toxicology...

Federal Grant Award Summary The National Institute on Aging awarded Brigham & Women's Hospital a $6.47 million Project Grant (R01) effective September 1, 2025 through August 31, 2030 under the Aging Research program (CFDA 93.866) to support the Ante-Amyloid Treatment of Alzheimer's Disease (A3) Trial and Alzheimer Plasma Extension (APEX) Study. The A3 Trial is a Phase IIB prevention study designed to test low-dose lecanemab, a monoclonal antibody that removes amyloid-beta, in cognitively...

Federal Cooperative Agreement Summary Weill Medical College of Cornell University received a $3.25 million Cooperative Agreement from the National Institute on Aging under the Aging Research program (CFDA 93.866) awarded April 1, 2026, with completion scheduled for March 31, 2028. The institution will conduct a Phase 1A clinical safety and dose-ranging trial of an adeno-associated virus (AAV) vector delivering a modified apolipoprotein E (APOE) gene therapy to the central nervous system of APOE4...

Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded $9.78 million to the Institute For Molecular Medicine Inc. on August 1, 2025, under the Aging Research program (CFDA 93.866) to conduct a multicenter Phase 1 clinical trial evaluating the safety and immunogenicity of AV-1980R/A, a preventive tau vaccine, in cognitively unimpaired preclinical Alzheimer's disease (AD) participants. The five-year project (through July 31, 2030) represents a strategic shift in AD...

The National Institute on Aging (NIA) awarded a $454,024 Project Grant (CFDA 93.866 - Aging Research) to the Research Foundation For Mental Hygiene, Inc. (RFMH) to conduct research on high-frequency oscillations (HFOs) as a potential biomarker for Alzheimer's disease progression. The key goals of this 2-year project are to: (1) determine if HFOs originate in the hippocampus and expand to other brain regions as Alzheimer's pathology advances, (2) assess whether disrupting HFOs can improve...

Tiaki Therapeutics Inc. was awarded a $1,099,720 cooperative agreement from the National Institute on Aging, part of the National Institutes of Health within the Department of Health and Human Services, to support research under the Aging Research program (CFDA 93.866). The award will fund the optimization of Tiaki's lead small molecule compounds that modulate sphingosine 1-phosphate receptor signaling to treat Alzheimer's disease by reducing neuroinflammation. Specifically, the funding will...

Federal Grant Award Summary Lighthouse Pharmaceuticals, Inc. received a $37.8 million Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866), awarded August 15, 2025, with completion targeted for July 31, 2029. The award funds a randomized, double-blind, placebo-controlled clinical study of LHP588 in subjects with Porphyromonas gingivalis (P. gingivalis)-positive Alzheimer's disease. The research builds on the company's prior development of atuzaginstat...

Federal Project Grant Award Summary Haima Therapeutics LLC received a $944,676 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective July 15, 2025, with a completion date of June 30, 2027. The award supports the development and advancement of Synthoplate (SP), a platelet-inspired synthetic hemostatic nanoparticle designed to restore hemostatic function in traumatic brain injury (TBI) patients...

Grant Award Summary Analytical Diagnostic Solutions Inc. received a $305,352 Project Grant award from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) effective July 1, 2025, through June 30, 2026. The company is developing HCY NOW, a quantitative point-of-care device for home-based monitoring of total blood homocysteine (THCy) levels to improve management of homocystinurias (HCUs)—inherited metabolic disorders characterized by plasma homocysteine accumulation. The...